Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1995; 74(01): 391-395
DOI: 10.1055/s-0038-1642709
DOI: 10.1055/s-0038-1642709
Symposium
Leukocytes, Thrombosis and Haemostasis
Tissue Factor Expression in Human Leukocytes and Tumor Cells
Further Information
Publication History
Publication Date:
09 July 2018 (online)
-
References
- 1 Rickies FR, Edwards RL. Leukocytes and Tumor Cells in Thrombosis. In: Hemostasis and Thrombosis.Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994: 1164-79
- 2 Nemerson Y. The Tissue Factor Pathway of Blood Coagulation. IBID 81-93
- 3 Ruf W, Edgington TS. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994; 8: 385-90
- 4 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology and expression of tissue factor. Thromb Haem 1991; 66: 67-79
- 5 Salzman EW, Hirsh J. The epidemiology, pathogenesis and natural history ofvenous thrombosis. In: Hemostasis and Thrombosis.. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. J.B. Lippincott Company; Philadelphia, PA: 1994: 1275-96
- 6 Rickies FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer and Metastasis Reviews 1992; 11: 237-48
- 7 Hancock WW, Gee D, de Moerloose P, Rickies FR, Ewan VA, Atkins RC. Immunohistological analysis of serial biopsies taken during human renal allograft rejection. Changing profile of infiltrating cells and activation of the coagulation system. Transplantation 1985; 39: 430-38
- 8 Rickies FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastatic agents. I. The role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulant and/or antiplatelet drags in cancer treatment. Sem Thromb Hemost 1988; 14: 88-94
- 9 Dvorak HF. Abnormalities of Hemostasis in Malignant Disease. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds J.B. Lippincott Company; Philadelphia, PA: 1994: 1238-54
- 10 Edwards RL, Levine JB, Green R, Duffy M, Matthews E, Brande W, Rickies FR. Activation of blood coagulation in Crohn's disease. Increased plasma fibrinopeptide A levels and enhanced generation of monocyte tissue factor activity. Gastroenterol 1987; 92: 329-37
- 11 Edwards RL, Rickies FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation J Lab Clin Med 1981; 98: 917-28
- 12 Neri Semeri GG, Abbate R, Gori AM, Attansio M, Martini F, Giusti B, Dabizzi P, Poggesi L, Modesti PA, Trotta F, Rostagno C, Boddi M, Gensini GF. Transient intermittent lymphocyte activation is responsibile for the instability of angina. Circulation 1992; 86: 790-97
- 13 Osterad B, Flagsted T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavorable prognos is. Thromb Haem 1983; 49: 5-12
- 14 Gambacorti-Passerini C, Cortellaro M, Cofrancesco E, Boschetti C, Pogliani E, Alessio G, Semeraro N, Mussoni L, Donati MB. Possible mechansisms of fibrin deposition in the hypereosinophilic syndrome. Haemos 1989; 1: 32-38
- 15 Courillon-Mallet A, Bevilacqua M, Wautier JL, Dervichian M, Cattan D, Caen J. Increased procoagulant response of monocytes from patients with Familial Mediterranean Fever. Thromb Haem 1986; 56: 211-17
- 16 Haire WD, Pirraccello SJ, Carson SD. Monocyte tissue factor in treated Hodgkin's disease. Leukemia & Lymphoma 1994; 12: 259-63
- 17 Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T. Tissue factor activity in leukemic cells. Special reference to disseminated intravascular coagulation. Cancer 1987; 59: 748-54
- 18 Cozzolino F, Torcia M, Miliani A, Carrossino AM, Giordani R, Cinotti S, Filimberti E, Saccardi R, Bemabei P, Guidi G, DiGuglielmo R, Pistoia V, Ferrarini M, Nawroth PP, Stem D. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute non-lymphocytic leukemia. Am J Med 1988; 84: 240-50
- 19 Bilgrami S, Greenberg BR, Weinstein RE, Hair GA, Rickies FR. Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: leukemic cell procoagulant activity is not responsible for the hypercoagulable state. Med Ped Oncol 1995; 24: 40-45
- 20 Tallman MS, Kwaan HC, Hakimian D, Rickies FR. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leukemia-Lymphoma 1993; 11: 27-36
- 21 Frankel SR, Eardley A, Heller G, Berman E, Miller Jr WH, Dmitrovsky E, Warrell Jr RP. All-trans retinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994; 120: 278-86
- 22 Rickies FR, Hair G, Schmeizl M, Kwaan H, Lanotte M, Tallman MS. All-trans retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells. Thromb Haem Suppl 1993; 69: 1042 Abstract
- 23 Falanga A, Consonni R, Marchetti M, Mielicki WP, Rambaldi A, Lanotte M, Gordon SG, Barbui T. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid. Leukemia 1994; 8: 156-59
- 24 Edwards RL, Rickies FR. Delayed hypersensitivity in man: effects of systemic anticoagulation. Science 1978; 200: 541-43
- 25 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim S-H, O’Donnell JF, O’Dell R, Tomyos K, Kwaan HC. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck and prostate: final report of VA Cooperative Study #75. Cancer 1984; 53: 2046-52
- 26 Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-89
- 27 Donovan-Peluso M, George LD, Hassett AC. Lipopolysaccharide induction of tissue factor expression in THP-1 monocytic cells. J Biol Chem 1994; 269: 1361-69
- 28 Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11: 4732-38
- 29 Mackman N, Fowler BJ, Edgington TS, Morrissey JH. Functional analysis of the human tissue factor promoter and induction by serum. ProcNatl Acad Sci USA 1990; 87: 2254-58
- 30 Oeth PA, Pany GC, Kunsch C, Nantermet P, Rosen CA, Mackman N. Lipopolysaccharide induction of tissue factor gene expression in monocytic cells is mediated by binding of c-Rel/p65 heterodimers to a kappa-B-like site. Mol Cell Biol 1994; 14: 3772-81
- 31 van der Logt CP E, Reitsma PH, Bertina RM. Alternative splicing is responsible for the presence of two tissue factor mRNA species in LPS stimulated human monocytes. Thromb Haemost 1992; 67: 272-79
- 32 Zioncheck TF, Soumitra R, Vehar GA. The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism. J Biol Chem 1992; 267: 3561-64
- 33 Paborsky LR, Harris RJ. Posttranslational modification of recombinant human tissue factor. Thromb Res 1990; 60: 367-76
- 34 Luhrs CA. The role of glycosylation in the biosynthesis and acquisition of ligand-binding activity of the folate-binding protein in cultured KB cells. Blood 1991; 77: 1171-80
- 35 Bona R, Lee E, Rickies F. Tissue factor apoprotein: intracellular transport and expression in shed membrane vesicles. Thromb. Res. 1987; 48: 487-500
- 36 Ewan VA, Cieplinski W, Hancock WW, Boyd AW, Goldschneider IG, Rickies FR. Production and characterization of a monoclonal antibody (A 1 -3) that binds selectively to activated monocytes and inhibits monocyte procoagulant activity. J Immunol 1986; 136: 2416-20
- 37 Hair GA, Schmeizl M, Distasio D, Zeff R, Rickies FR. N-linkedglycosylation is required for membrane expression of cellular tissue factor. Clin Res 1994; 42: 183 A
- 38 Paborsky LR, Fendly BM, Fisher KL, Lawn RM, Marks BJ, McCray G, Tate KM, Vehar GA, Gorman CM. Mammalian cell transient expression of tissue factor for the production of antigen. Prot Eng 1990; 3: 547-53
- 39 Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res 1989; 56: 425-30
- 40 Hair GA, Padula S, Zeff R, Schmeizl M, Contrino J, Kreutzer DL, de Moerloose P, Boyd AW, Stanley I, Burgess AW, Rickies FR. Tissue factor expression in human leukemic cells. Leuk Res In Press; 1995
- 41 Fenderson BA, Andrews PW. Carbohydrate antigens of embryonal carcinoma cells; changes upon differentiation. APMIS Suppl (Suppl. 27) 1992; 100: 109-18
- 42 Liu CK, Schmied R, Schreiber C, Rosen A, Qian GX, Waxman S. Glycosyltransferase alterations are cell type related when human promyelocytic leukemia (HL-60) cells are treated with various inducers of differentiation. Exp Hematol 1983; 11: 738-46
- 43 van der Besselaar AM H P, Bertina RM. Interaction of thromboplastin apoprotein of different tissues with concanavalin A - evidence for heterogenous glycosylation of the human apoprotein. Thromb Haemost 1984; 52: 192-95
- 44 Paulson JC, Colleyk J. Glycosyltransferases; structures, localization and control of cell type-specific glycosylation. J Biol Chem 1989; 264: 17615-18
- 45 Konrad M, Merz WE. Regulation of N-glycosylation. J Biol Chem 1994; 269: 8659-8666